Rapport Therapeutics (NASDAQ:RAPP) Stock: Insider Abraham Ceesay Sells 2,210 Shares

Key Points

• CEO Abraham Ceesay sold 2,210 Rapport Therapeutics shares at an average price of $39.17, generating $86,565.70. After the sale, he still directly owned 456,767 shares valued at approximately $17.9 million.
• RAPP shares fell 0.9% to $33.83, while the company reported a quarterly loss of $1.19 per share, missing analyst expectations of a $1.12 loss.
• Analyst sentiment remains broadly positive, with an average rating of “Buy” and a consensus price target of $66.25, despite some sell ratings and recent insider selling.

Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) CEO Abraham Ceesay sold 2,210 shares of the business's stock in a transaction on Wednesday, September 23rd. The shares were sold at an average price of $39.17, for a total transaction of $86,565.70. Following the sale, the chief executive officer directly owned 456,767 shares in the company, valued at $17,891,563.39. This trade represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Abraham Ceesay also recently made the following trade(s):

• On Tuesday, September 8th, Abraham Ceesay sold 8,210 shares of Rapport Therapeutics stock. The shares were sold at an average price of $45.61, for a total value of $374,458.10.
• On Tuesday, August 25th, Abraham Ceesay sold 18,921 shares of Rapport Therapeutics stock. The stock was sold at an average price of $49.57, for a total value of $937,913.97.
• On Tuesday, August 11th, Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock. The stock was sold at an average price of $48.01, for a total value of $1,390,273.58.
• On Monday, August 10th, Abraham Ceesay sold 22,541 shares of Rapport Therapeutics stock. The shares were sold at an average price of $46.26, for a total value of $1,042,746.66.
• On Monday, July 27th, Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock. The shares were sold at an average price of $42.11, for a total value of $93,063.10.

Rapport Therapeutics Stock Down 0.9%

Shares of NASDAQ:RAPP traded down $0.30 during trading on Thursday, hitting $33.83. The stock had a trading volume of 848,481 shares, compared to its average volume of 353,622. Rapport Therapeutics, Inc. has a 12-month low of $23.75 and a 12-month high of $52.93. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -11.13 and a beta of 1.02. The stock has a 50-day simple moving average of $44.73 and a two-hundred day simple moving average of $38.82.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.07). As a group, sell-side analysts forecast that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on RAPP shares. Wall Street Zen cut shares of Rapport Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Citigroup reaffirmed a "market outperform" rating on shares of Rapport Therapeutics in a research report on Wednesday. HC Wainwright lifted their price objective on Rapport Therapeutics from $40.00 to $66.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. Weiss Ratings reissued a "sell (d-)" rating on shares of Rapport Therapeutics in a report on Friday, July 17th. Finally, UBS Group set a $80.00 target price on Rapport Therapeutics in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Rapport Therapeutics has an average rating of "Buy" and an average price target of $66.25.

Institutional Investors Weigh In On Rapport Therapeutics

Institutional investors have recently modified their holdings of the business. Algert Global LLC purchased a new position in Rapport Therapeutics during the second quarter worth approximately $9,327,000. Johnson & Johnson purchased a new stake in shares of Rapport Therapeutics in the second quarter valued at approximately $74,360,823. Walleye Capital LLC purchased a new stake in shares of Rapport Therapeutics in the second quarter valued at approximately $4,257,000. Legal & General Group Plc acquired a new position in shares of Rapport Therapeutics during the 2nd quarter worth approximately $940,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of Rapport Therapeutics by 168.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 224,498 shares of the company's stock worth $7,025,000 after buying an additional 141,011 shares during the period.

Rapport Therapeutics Company Profile

Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for disorders of the central nervous system. The company's research centers on receptor-associated proteins, which help regulate neurotransmitter receptors and may provide opportunities to develop more selective therapies than those that target receptors broadly.

Rapport's lead development program, RAP-219, is an orally administered investigational therapy designed to modulate AMPA receptors through their associated proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.